BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...of Toronto team including Leah Cowen and Luke...
BioCentury | Sep 22, 2020

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...were at the forefront of discovering the broad potential of inflammasome inhibition. Co-founder and CSO Luke...
BioCentury | Aug 14, 2020

OSI leverages foundational deal with Oxford to build its life sciences portfolio principal after being an associate and entrepreneur-in-residence at Atlas Venture. The firm recently added Luke...
BioCentury | Jul 21, 2020

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...CEO of Rubius Therapeutics Inc. (NASDAQ:RUBY). Clarke succeeded Cagnoni at Tizona in January 2019; MPM’s Luke...
BioCentury | Feb 27, 2020

MPM, Dana-Farber forge philanthropic arrangement around new oncology funds

...and Mal Salter, had long sought a solution. The idea was hatched years ago; MPM's Luke...
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting stress response protein YCK2 to overcome antifungal resistance

...A team led by Bright Angel Therapeutics Inc. co-founder Leah Cowen, and including fellow co-founder Luke...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...conditionally activated cytokines, or Indukines, against well-validated targets, most likely in solid tumors. MPM Capital’s Luke...
BioCentury | Sep 24, 2019
Financial News

Amphivena to expand clinical program, T cell engager pipeline with $62M series C

...“AMV564 also eliminates the MDSC population rather than block biochemical pathways related to MDSCs.” MPM’s Luke...
BioCentury | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

...San Francisco, Calif. e-mail: CONTACT: Luke Gilbert, University of California, San Francisco, Calif. e-mail: Inhua...
BioCentury | Jun 25, 2019

Frontier aims for previously unreachable ‘hot spot’ targets with $67M series A

...of targets, while Roberto Zoncu has studied cellular function and growth regulation in cancer. MPM’s Luke...
...we can find our way to one or two ‘win-win’ kinds of deals relatively early.” Luke...
Items per page:
1 - 10 of 105